Cisplatin or not in advanced gastric cancer: a systematic review and meta-analysis

scientific article

Cisplatin or not in advanced gastric cancer: a systematic review and meta-analysis is …
instance of (P31):
scholarly articleQ13442814
meta-analysisQ815382
systematic reviewQ1504425
review articleQ7318358

External links are
P819ADS bibcode2013PLoSO...883022P
P356DOI10.1371/JOURNAL.PONE.0083022
P932PMC publication ID3873906
P698PubMed publication ID24386137
P5875ResearchGate publication ID259567616

P50authorGiovanni SgroiQ64786032
Fausto PetrelliQ88397153
Sandro BarniQ114372608
Mary CabidduQ115137157
Mara GhilardiQ115137161
Andrea CoinuQ115137170
P2093author name stringAlberto Zaniboni
P2860cites workA randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapyQ83979395
Chemotherapy for advanced gastric cancerQ24236634
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialQ27851578
Extracting summary statistics to perform meta-analyses of the published literature for survival endpointsQ27860640
Practical methods for incorporating summary time-to-event data into meta-analysisQ28131754
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysisQ30586297
Aggregate data meta-analysis with time-to-event outcomesQ30742997
Capecitabine and oxaliplatin for advanced esophagogastric cancer.Q33313072
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junctionQ33380002
Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer.Q33382794
S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysisQ33605846
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patientsQ33849656
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer ResearchQ34581504
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junctionQ34609932
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trialQ34634936
Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancerQ36075265
Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysisQ37845734
Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trialsQ38034487
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.Q38059698
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de CancerQ45130075
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II studyQ45154773
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische OnkologieQ46694609
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue12
P407language of work or nameEnglishQ1860
P921main subjectcisplatinQ412415
systematic reviewQ1504425
antineoplasticQ2853144
stomach neoplasmQ4335552
P5008on focus list of Wikimedia projectScienceSourceQ55439927
P304page(s)e83022
P577publication date2013-12-27
P1433published inPLOS OneQ564954
P1476titleCisplatin or not in advanced gastric cancer: a systematic review and meta-analysis
P478volume8

Reverse relations

cites work (P2860)
Q53492933A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Q38604012Chemotherapy for advanced gastric cancer.
Q38747484FTIR Biospectroscopy Investigation on Cisplatin Cytotoxicity in Three Pairs of Sensitive and Resistant Cell Line
Q42125510Gastric cancer: toward a cisplatin-free disease?
Q37718510Management of advanced gastric cancer: An overview of major findings from meta-analysis.
Q34444812Nephroprotective effect of gelsemine against cisplatin-induced toxicity is mediated via attenuation of oxidative stress
Q36275825Puerarin attenuates cisplatin-induced rat nephrotoxicity: The involvement of TLR4/NF-κB signaling pathway
Q36741735Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy
Q61795899The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis
Q38941416The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis

Search more.